Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$7.14
+4.3%
$6.72
$5.73
$14.38
$586.84M0.84431,368 shs172,470 shs
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
$88.06
-0.4%
$87.69
$77.67
$99.51
$611.21M0.72279,396 shs280,857 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
0.00%+5.52%+9.74%-14.24%+21.29%
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
0.00%+0.67%-0.40%+4.96%-2.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
2.7063 of 5 stars
3.30.00.00.00.04.21.3
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.67
Moderate Buy$14.33100.63% Upside
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
2.66
Moderate Buy$88.06N/A

Current Analyst Ratings Breakdown

Latest PRSM, BVS, PPH, ISX, and IHP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$15.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$567.70M1.03$0.57 per share12.58$2.80 per share2.55
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23M-$0.48N/A15.53N/A-7.11%15.61%4.01%N/A
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/AN/A20.21N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
$1.952.21%N/AN/AN/A

Latest PRSM, BVS, PPH, ISX, and IHP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/30/2025
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
Quarterly$0.60692.75%7/1/20257/1/20257/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/A

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.14 million54.46 millionNot Optionable
VanEck Pharmaceutical ETF stock logo
PPH
VanEck Pharmaceutical ETF
147,0006.94 millionN/AOptionable

Recent News About These Companies

PPH, Big Pharma Stocks Volatile on Trump Drug Pricing
(PPH) Investment Report
PPH Is a Pertinent Healthcare Idea for 2025
(PPH) Pivots Trading Plans and Risk Controls
When the Price of (PPH) Talks, People Listen
Diversified Exposure To The Weight Loss Drug Market
Healthcare ETFs Starting to Look Healthy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioventus stock logo

Bioventus NYSE:BVS

$7.14 +0.29 (+4.29%)
As of 07/3/2025 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

VanEck Pharmaceutical ETF stock logo

VanEck Pharmaceutical ETF NASDAQ:PPH

$88.06 -0.33 (-0.37%)
Closing price 07/3/2025 03:46 PM Eastern
Extended Trading
$88.13 +0.07 (+0.09%)
As of 07/3/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.